EGFR and gastric cancer: Li et al. (2017) also found that low expression of ARHGAP10 can lead to cisplatin resistance in gastric cancer cell lines. These studies suggested that ARHGAP10 was involved in the regulation of drug resistance. Cdc42 can activate and increase Ras and EGFR signaling, and Cdc42 is a putative therapeutic target in breast, colon, lung cancer and pancreatic cancers (Aguilar, Zhou & Lu, 2017). In a recent study, Cdc42 was reported as a promising target for cancer treatment (Maldonado & Dharmawardhane, 2018).